221 related articles for article (PubMed ID: 24010873)
21. Evidence on the relationship between PROMIS-29 and EQ-5D: a literature review.
Pan T; Mulhern B; Viney R; Norman R; Tran-Duy A; Hanmer J; Devlin N
Qual Life Res; 2022 Jan; 31(1):79-89. PubMed ID: 34181154
[TBL] [Abstract][Full Text] [Related]
22. Mapping analysis to predict EQ-5D-5 L utility values based on the Oxford Hip Score (OHS) and Oxford Knee Score (OKS) questionnaires in the Spanish population suffering from lower limb osteoarthritis.
Martín-Fernández J; Morey-Montalvo M; Tomás-García N; Martín-Ramos E; Muñoz-García JC; Polentinos-Castro E; Rodríguez-Martínez G; Arenaza JC; García-Pérez L; Magdalena-Armas L; Bilbao A
Health Qual Life Outcomes; 2020 Jun; 18(1):184. PubMed ID: 32539838
[TBL] [Abstract][Full Text] [Related]
23. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments.
Kontodimopoulos N; Aletras VH; Paliouras D; Niakas D
Value Health; 2009; 12(8):1151-7. PubMed ID: 19558372
[TBL] [Abstract][Full Text] [Related]
24. Mapping EORTC QLQ-C30 onto EQ-5D for the assessment of cancer patients.
Kim SH; Jo MW; Kim HJ; Ahn JH
Health Qual Life Outcomes; 2012 Dec; 10():151. PubMed ID: 23244763
[TBL] [Abstract][Full Text] [Related]
25. Mapping the 25-item National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25) to EQ-5D utility scores.
Kay S; Ferreira A
Ophthalmic Epidemiol; 2014 Apr; 21(2):66-78. PubMed ID: 24568628
[TBL] [Abstract][Full Text] [Related]
26. Mapping function from FACT-B to EQ-5D-5 L using multiple modelling approaches: data from breast cancer patients in China.
Yang Q; Yu XX; Zhang W; Li H
Health Qual Life Outcomes; 2019 Oct; 17(1):153. PubMed ID: 31615531
[TBL] [Abstract][Full Text] [Related]
27. Estimating the association between SF-12 responses and EQ-5D utility values by response mapping.
Gray AM; Rivero-Arias O; Clarke PM
Med Decis Making; 2006; 26(1):18-29. PubMed ID: 16495197
[TBL] [Abstract][Full Text] [Related]
28. Mapping the EORTC QLQ-C30 onto the EQ-5D-3L: assessing the external validity of existing mapping algorithms.
Doble B; Lorgelly P
Qual Life Res; 2016 Apr; 25(4):891-911. PubMed ID: 26391884
[TBL] [Abstract][Full Text] [Related]
29. Mapping the Minnesota living with heart failure questionnaire (MLHFQ) to EQ-5D-5L in patients with heart failure.
Kularatna S; Senanayake S; Chen G; Parsonage W
Health Qual Life Outcomes; 2020 Apr; 18(1):115. PubMed ID: 32349782
[TBL] [Abstract][Full Text] [Related]
30. An assessment of the external validity of mapping QLQ-C30 to EQ-5D preferences.
Crott R; Versteegh M; Uyl-de-Groot C
Qual Life Res; 2013 Jun; 22(5):1045-54. PubMed ID: 22743734
[TBL] [Abstract][Full Text] [Related]
31. Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences.
Crott R; Briggs A
Eur J Health Econ; 2010 Aug; 11(4):427-34. PubMed ID: 20473703
[TBL] [Abstract][Full Text] [Related]
32. Mapping DLQI on EQ-5D in psoriasis: transformation of skin-specific health-related quality of life into utilities.
Blome C; Beikert FC; Rustenbach SJ; Augustin M
Arch Dermatol Res; 2013 Apr; 305(3):197-204. PubMed ID: 23266843
[TBL] [Abstract][Full Text] [Related]
33. Comparison of FACT- and EQ-5D-based utility scores in cancer.
Pickard AS; Ray S; Ganguli A; Cella D
Value Health; 2012; 15(2):305-11. PubMed ID: 22433762
[TBL] [Abstract][Full Text] [Related]
34. A mapping study in mainland China: predicting EQ-5D-5L utility scores from the psoriasis disability index.
Su J; Liu T; Li S; Zhao Y; Kuang Y
J Med Econ; 2020 Jul; 23(7):737-743. PubMed ID: 32223358
[No Abstract] [Full Text] [Related]
35. Testing mapping algorithms of the cancer-specific EORTC QLQ-C30 onto EQ-5D in malignant mesothelioma.
Arnold DT; Rowen D; Versteegh MM; Morley A; Hooper CE; Maskell NA
Health Qual Life Outcomes; 2015 Jan; 13():6. PubMed ID: 25613110
[TBL] [Abstract][Full Text] [Related]
36. Mapping the cancer-specific EORTC QLQ-C30 and EORTC QLQ-BR23 to the generic EQ-5D in metastatic breast cancer patients.
Kim EJ; Ko SK; Kang HY
Qual Life Res; 2012 Sep; 21(7):1193-203. PubMed ID: 22012023
[TBL] [Abstract][Full Text] [Related]
37. Longitudinal predictive ability of mapping models: examining post-intervention EQ-5D utilities derived from baseline MHAQ data in rheumatoid arthritis patients.
Kontodimopoulos N; Bozios P; Yfantopoulos J; Niakas D
Eur J Health Econ; 2013 Apr; 14(2):307-14. PubMed ID: 22252308
[TBL] [Abstract][Full Text] [Related]
38. Mapping MOS-HIV to HUI3 and EQ-5D-3L in Patients With HIV.
Joyce VR; Sun H; Barnett PG; Bansback N; Griffin SC; Bayoumi AM; Anis AH; Sculpher M; Cameron W; Brown ST; Holodniy M; Owens DK
MDM Policy Pract; 2017; 2(2):2381468317716440. PubMed ID: 30288427
[No Abstract] [Full Text] [Related]
39. Mapping health outcome measures from a stroke registry to EQ-5D weights.
Ghatnekar O; Eriksson M; Glader EL
Health Qual Life Outcomes; 2013 Mar; 11():34. PubMed ID: 23496957
[TBL] [Abstract][Full Text] [Related]
40. 'Mapping' Health State Utility Values from Non-preference-Based Measures: A Systematic Literature Review in Rare Diseases.
Meregaglia M; Whittal A; Nicod E; Drummond M
Pharmacoeconomics; 2020 Jun; 38(6):557-574. PubMed ID: 32152892
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
